Your SlideShare is downloading. ×
  • Like
Georgetown University Hospital Dept of Medicine Grand Rounds
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Georgetown University Hospital Dept of Medicine Grand Rounds

  • 710 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
710
On SlideShare
0
From Embeds
0
Number of Embeds
2

Actions

Shares
Downloads
7
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Sponsored by:Creutzfeldt-Jakob diseaseDiagnosis and Management of Prion Diseases March 21, 2013 Brian S. Appleby, M.D. Lou Ruvo Center for Brain Health Cleveland Clinic
  • 2. Disclosures• No relevant financial disclosures• Off-label uses of: • Quinacrine • Pentosan Polysulphate • Doxycycline
  • 3. ObjectivesI. Understand key elements of diagnosing CJDII. Demonstrate strategies for managing patients with CJDIII. Demonstrate knowledge regarding CJD risks
  • 4. “Pri-on”• proteinaceous and infectious• -ion (infectious, e.g. virion)• No nucleic acid• Non-degradable by typical sterilization
  • 5. Soto C, Trends Biochem Sci 2006
  • 6. Etiologies Kuru Genetic CJD Iatrogenic CJD Fatal familial insomnia Variant CJD Gerstmann-Sträussler-Scheinker
  • 7. Age at Onset sCJD gCJD vCJDAdapted from: Appleby BS, J Neuropsychiatry Clin Neurosci 2007
  • 8. Epidemiology sCJD=1/1,000,000 people per year1/10,000 deaths per year in US due to CJD
  • 9. Survival Time Adapted from: Appleby BS, Arch Neurol 2009
  • 10. Definitive DiagnosisH&E Immunohistochemistry
  • 11. Probable sCJDAt least two clinical signs:1.Dementia2.Cerebellar or visual symptoms3.Pyramidal or extrapyramidal symptoms4.Akinetic mutismAt least one of the following:1.PSWCs on EEG2.14-3-3 in CSF and disease duration < 2 years3.High signal abnormalities in basal ganglia or at least twocortical regions (temporal, parietal, or occipital) onDWI/FLAIR sequences on brain MRI Zerr I, et al. Brain 2009
  • 12. Electroencephalogram (EEG) Periodic sharp wave complexes (PSWC’s)
  • 13. MRI (DWI/FLAIR)
  • 14. All stage CJDEarly stage CJD Satoh K, Dement Geriatr Cog Disord 2007
  • 15. Genetic Prion Disease Kovács GG, J Neurol 2002
  • 16. Acquired Prion Disease• Kuru• Iatrogenic CJD (iCJD)• Variant CJD (vCJD)
  • 17. Kuru
  • 18. Iatrogenic CJD Brown P, Neurology 2006
  • 19. Variant CJD227 total cases http://www.cjd.ed.ac.uk/vcjdworld.htm
  • 20. vCJD Characteristics Will RG, Lancet 1996
  • 21. Pulvinar Sign Zeidler M, Lancet 2000
  • 22. MM MV BSE1980’s Creutzfeldt-Jakob Disease in the UK, 18th Annual Report, 2009
  • 23. Chronic Wasting Disease
  • 24. Experimental Treatment• Quinacrine and other tricyclic compounds• Pentosan polysulphate (PPS)• Doxycycline
  • 25. QuinacrineI. 30 sCJD/2vCJD, no sig diff in survival time (Haik S, Neurology, 2004)II. PRION-1 (UK), 45 sCJD/2 iCJD, 18 vCJD, 42 gCJD, no sig diff in survival time (Collinge J, Lancet Neurol, 2009)III. UCSF, midpoint survival analyses, no sig diff btwn comparison groups (Log rank, p=0.4) (Geschwind M, 6th CJD Family Conference, 2008)
  • 26. 45 sCJD, 42 genetic prion disease, 18 vCJD, 2 iCJD Quinacrine PO 1g/24hr then Quinacrine 100mg PO TID Only 2 of 107 subjects chose randomization
  • 27. “PRION-1 was essentially an observational study of patients choosing to take quinacrine or not...” Collinge J, Lancet Neurol 2009
  • 28. Doh-ura K, J Virol 2004
  • 29. Pentosan Polysulphate Bone I, Eur J Neurol 2008
  • 30. “On the basis of the available evidence, thebest possible outcome that could be expectedafter treatment with intraventricular PPS isthat there may be some temporary slowing orhalting of the disease progression. However,there is little likelihood of significant clinicalimprovement. Nor is there a likelihood ofpermanent halting of disease progression.” CJD Support Network Newsletter, March 2004
  • 31. DoxycyclineObservational study Group Number of cases Median survival timeDoxycycline treated 21 292 daysUntreated 581 169 days Log Rank test, p<0.001 PRNP codon 129 MM, p=0.019 MV, p=0.133 VV, p=0.54 Zerr I, Prion 2008, Madrid, Spain
  • 32. Care and Management
  • 33. Goals EducationCommunication Implementation
  • 34. Intervals of CareI. Pre-clinical/Presentation PhaseII. Diagnostic PhaseIII. Caring Phase
  • 35. Preclinical/Presentation Phase• Initial interactions with primary medical doctor• At risk individuals should identify “physician champions” Kranitz FJ & Simpson DM. CNS Neurol Disord Drug Targets 2009
  • 36. Diagnosis Phase• Discuss process with patient and family• Don’t forget about present needs• Referto organizations and clinicians familiar with the illness• Discharge planning (before discharge)• Must establish a “key worker” Douglas M, Patients with nvCJD and their families 1999
  • 37. Caring Phase• Frequentreassessment/symptomatic treatment• Limitvisits to few individuals of short durations• Assess caregiver requirements• Hospice/Respite care
  • 38. Symptomatic TreatmentSymptom Suggested TreatmentPsychosis/Agitation Low potency neuroleptics (e.g., quetiapine)Myoclonus/Hyperstartle Long acting benzodiazepines (e.g., diazepam) Anticonvulsants (e.g., valproic acid)Seizures AnticonvulsantsDystonia/Contractures Passive movement Long acting benzodiazepines, Botulinum toxin injectionsConstipation Bowel regimen (e.g., dulcolax)Dysphagia/Rumination Thickener, cueing Behavioral/Environmental changes first Start low and go slow Re-evaluate frequently
  • 39. Afterwards• Arrange requested post-mortems prior to death (www.cjdsurveillance.com)• Frequent check-ins with family/caregivers• Ifpostmortem performed, communicate results (in person if possible)• Encourage contact as needed
  • 40. Risk Assessment
  • 41. Routine Clinical Care• Standard Precautions Only• No need for gowns, masks, isolation, etc.• Consider the family
  • 42. Surgery/Equipment• WHO. WHO consultation on TSE in relation to biological and pharmaceutical products. Geneva, Switzerland; 2003• WHO. WHO guidelines on tissue infectivity distribution in TSE. Geneva, Switzerland; 2005• Transfusion Medicine Epidemiological Review (TMER) ( http://www.cjd.ed.ac.uk/TMER/TMER.htm)
  • 43. Case• 57 y.o. AAM professional, h/o 3 TBI’s• Some short term memory problems x 3 months• More distractible, still working full time• MMSE=24/30 (-1 calculation, -3 orientation, -2 recall)• mild left upper extremity dysmetria
  • 44. Summary• Diagnosing CJD can be difficult and frustrating• Getting a proper diagnosis and managing the care of a patient with CJD is stressful• Care and management of patients with prion disease is supportive and entails several disease specific interventions
  • 45. Thank You!